Hope for hematological diseases

Cellular immunotherapy as a beacon of hope for hematological malignancies

Recently, successful cancer immunotherapy has aroused great interest in application of this approach in hematological malignancies. Immune responsiveness is a key clinical feature of hematological malignancies. Indeed, the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) largely derives from graft-versus-tumor effects that highlight the ability of the immune system to speci...

Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?

[Human herpesvirus 6 in hematological diseases].

The huge amount of experimental and clinical observations supporting the possible involvement of human herpesvirus 8 (HHV-8) or Kaposi sarcoma herpesvirus (KSHV) in human lymphoproliferative diseases was critically reviewed during a workshop organized by the Italian Society for Experimental Hematology in Florence, Italy, on July 3rd, 1997. The organizers have prepared this report for the reader...

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.

Certain patients with antibody-mediated autoimmune disease exhibit poor responses to conventional immunosuppression, including B-cell depletion with rituximab. Proteasome inhibitors such as bortezomib demonstrate pleiotropic immunomodulatory effects, including direct toxicity to antibody-producing cells. Here, we report preliminary evidence for the efficacy of bortezomib as salvage therapy for ...

The relationship between periodontitis and systemic diseases - hype or hope?

Investigations have definitely acknowledged a clinically relevant two-way relationship between periodontitis and certain systemic diseases and conditions, which are significant for the dentist in the daily practice and for a physician as well. This review article yields the most up-to-date information on the role of periodontal diseases in systemic diseases, that include cardiovascular diseases...